A revision to F-star’s agreement with Merck KGaA has propelled the UK-based bispecific antibody specialist on a new course to develop a proprietary pipeline, its CEO said.
The 2017 immuno-oncology R&D collaboration with Merck KGaA granted the German group exclusive development and commercial rights to five novel...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
